secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2026-06-22T10:50:13+00:00
Accession:  0001104659-26-076044
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure reports AMT-260 Phase I/IIa data: 3/6 patients saw 79-100% seizure reduction; no SAEs
--------------------------------------------------------------------------------

- Three of six patients in low-dose cohort achieved 79% to 100% decline in disabling seizures (months 4-6).
- Remaining three patients had variable changes: -33% to +36% from baseline.
- No serious adverse events related to AMT-260 or surgery; all AEs mild/moderate, headache most common (N=2).
- Enrollment ongoing for second, higher-dose cohort (3x10¹² gc/mL), expected completion mid-2026; updated results H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/0001104659-26-076044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/qure-20260619x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer